4.7 Article

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 40, Issue 2, Pages 259-267

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2014.261

Keywords

-

Funding

  1. AstraZeneca
  2. Avanier Pharmaceuticals
  3. Bristol-Myers Squibb
  4. Eli Lilly
  5. Hoffman La-Roche
  6. Merck
  7. Naurex
  8. Noven Pharmaceuticals
  9. Takeda
  10. Sanofi-Aventis
  11. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH081211] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Large 'real world' studies demonstrating the limited effectiveness and slow onset of clinical response associated with our existing antidepressant medications has highlighted the need for the development of new therapeutic strategies for major depression and other mood disorders. Yet, despite intense research efforts, the field has had little success in developing antidepressant treatments with fundamentally novel mechanisms of action over the past six decades, leaving the field wary and skeptical about any new developments. However, a series of relatively small proof-of-concept studies conducted over the last 15 years has gradually gained great interest by providing strong evidence that a unique, rapid onset of sustained, but still temporally limited, antidepressant effects can be achieved with a single administration of ketamine. We are now left with several questions regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action. In this Circumspectives piece, Dr Sanacora and Dr Schatzberg share their opinions on these issues and discuss paths to move the field forward.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available